Gender-specific data on the management of HIV infection are scarce. Further, an increase in the proportion of new HIV diagnoses in older persons has been observed. Using data from the CoRIS cohort, we compared immunovirological responses and survival in HIV-infected men and women who started their first combination anti-retroviral therapy (cART) when aged </≥50 years.
Methods
We used multivariable logistic, linear and Cox regression, adjusting for potential confounders and including an interaction between age and sex, to assess differences in immunovirological responses and mortality, respectively.
Results
At 96 weeks, among subjects <50 years, women were less likely than men to achieve virological response (VR; adjusted OR [aOR] 0.77, 95% CI 0.60, 0.99) and among women, older individuals were more likely to achieve VR than the younger ones (aOR 1.96; 95% CI 1.15, 3.34). Initiating cART at ≥50 years was associated with lower increases in CD4+ T-cell count both in men (-65.8; 95% CI -91.3, -40.3) and women (-37.7; 95% CI -79.7, 4.4) and women showed higher increases than men in both subjects aged <50 (21.8; 95% CI -1.9, 45.5) and ≥50 years at cART initiation (49.9; 95% CI 19.9, 79.9). A higher risk of death in men ≥50 was observed (adjusted hazard ratio [aHR] 2.69; 95% CI 1.73, 4.21), but not in women (aHR 1.49; 95% CI 0.70, 1.14). Women experienced lower mortality than men <50 (0.66; 95% CI 0.41, 1.07) and in those ≥50 (0.37; 95% CI 0.14, 0.93).
Conclusions
Sex and age at cART initiation have a noticeable association with both virological and immunological responses and mortality. Age ≥50 is associated with poorer immunological response and higher mortality but this effect is less pronounced in women than in men.
References
1.
LohseN., HansenA.B., PedersenG.Survival of persons with and without HIV infection in Denmark, 1995–2005.Ann Intern Med2007; 146: 87–95.
2.
PorterK., BabikerA., BhaskaranK.Determinants of survival following HIV-1 seroconversion after the introduction of HAART.Lancet2003; 362: 1267–1274.
3.
DeeksS.G., LewinS.R., HavlirD.V.The end of AIDS: HIV infection as a chronic disease.Lancet2013; 382: 1525–1533.
4.
BrooksJ.T., BuchaczK., GeboK.A., MerminJ.HIV infection and older Americans: the public health perspective.Am J Public Health2012; 102: 1516–1526.
5.
HighK.P., Brennan-IngM., CliffordD.B.HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group.J Acquir Immune Defic Syndr2012; 60Suppl 1: S1–S18.
6.
SmitM., BrinkmanK., GeerlingsS.Future challenges for clinical care of an ageing population infected with HIV: a modelling study.Lancet Infect Dis2015; 15: 810–818.
7.
HaberlA., JohnsonM., DominguezS., MirallesC., MonforteA., AndersonJ.The need for data on women living with HIV in Europe.Antivir Ther2013; 18Suppl 2: 1–10.
8.
SoonG.G., MinM., StrubleK.A.Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008).AIDS Patient Care STDS2012; 26: 444–453.
9.
KojicE.M., WangC.C., Cu-UvinS.HIV and menopause: a review.J Womens Health (Larchmt)2007; 16: 1402–1411.
10.
Sobrino-VegasP., GutierrezF., BerenguerJ.[The Cohort of the Spanish HIV Research Network (CORIS) and its associated biobank; organizational issues, main findings and losses to follow-up].Enferm Infecc Microbiol Clin2011; 29: 645–653. Spanish.
BlancoJ.R., JarrinI., VallejoM.Definition of advanced age in HIV infection: looking for an age cut-off.AIDS Res Hum Retroviruses2012; 28: 1000–1006.
13.
de PommerolM., HessamfarM., Lawson-AyayiS.Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort.Int J STD AIDS2011; 22: 67–72.
14.
FantryL.E., ZhanM., TaylorG.H., SillA.M., FlawsJ.A.Age of menopause and menopausal symptoms in HIV-infected women.AIDS Patient Care STDS2005; 19: 703–711.
15.
FerreiraC.E., Pinto-NetoA.M., CondeD.M., Costa-PaivaL., MoraisS.S., MagalhaesJ.Menopause symptoms in women infected with HIV: prevalence and associated factors.Gynecol Endocrinol2007; 23: 198–205.
16.
SchoenbaumE.E., HartelD., LoY.HIV infection, drug use, and onset of natural menopause.Clin Infect Dis2005; 41: 1517–1524.
17.
PattersonK., NapravnikS., EronJ., KerulyJ., MooreR.Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy.HIV Med2007; 8: 406–410.
18.
AlthoffK.N., JusticeA.C., GangeS.J.Virologic and immunologic response to HAART, by age and regimen class.AIDS2010; 24: 2469–2479.
19.
GrabarS., KousignianI., SobelA.Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.AIDS2004; 18: 2029–2038.
20.
GreenbaumA.H., WilsonL.E., KerulyJ.C., MooreR.D., GeboK.A.Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals.AIDS2008; 22: 2331–2339.
21.
SabinC.A., SmithC.J., d'ArminioM.A.Response to combination antiretroviral therapy: variation by age.AIDS2008; 22: 1463–1473.
22.
CollazosJ., AsensiV., CartonJ.A.Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.AIDS2007; 21: 835–843.
23.
MooreA.L., KirkO., JohnsonA.M.Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited.J Acquir Immune Defic Syndr2003; 32: 452–461.
24.
NicastriE., AngelettiC., PalmisanoL.Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy.AIDS2005; 19: 577–583.
25.
EggerM., MayM., CheneG.Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Lancet2002; 360: 119–129.
26.
Antiretroviral Therapy Cohort Collaboration (ART-CC).Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.Antivir Ther2015; 20: 21–28.
27.
AbioyeA.I., SoipeA.I., SalakoA.A.Are there differences in disease progression and mortality among male and female HIV patients on antiretroviral therapy? A meta-analysis of observational cohorts.AIDS Care2015; 27: 1468–1486.
28.
PattersonK.B., CohnS.E., UyanikJ., HughesM., SmurzynskiM., EronJ.J.Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies.Clin Infect Dis2009; 49: 473–476.
29.
CalvetG.A., VelasqueL., LuzP.M.Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil.PLoS One2014; 9: e89299.
30.
GiglioT., ImroM.A., FilaciG.Immune cell circulating subsets are affected by gonadal function.Life Sci1994; 54: 1305–1312.
31.
SafadiF.F., DissanayakeI.R., GoodmanG.G.Influence of estrogen deficiency and replacement on T-cell populations in rat lymphoid tissues and organs.Endocrine2000; 12: 81–88.
32.
AsinS.N., HeimbergA.M., EszterhasS.K., RollenhagenC., HowellA.L.Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells.AIDS Res Hum Retroviruses2008; 24: 701–716.
33.
KatagiriD., HayashiH., VictorianoA.F., OkamotoT., OnozakiK.Estrogen stimulates transcription of human immunodeficiency virus type 1 (HIV-1).Int Immunopharmacol2006; 6: 170–181.
34.
van BenthemB.H., VernazzaP., CoutinhoR.A., PrinsM.The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women.AIDS2002; 16: 919–924.
Pérez-ElíasM.J., MurielA., MorenoA.Relevant gender differences in epidemiological profile, exposure to first antiretroviral regimen and survival in the Spanish AIDS Research Network Cohort.Antivir Ther2014; 19: 375–385.
